COMPANY PROFILE / BIOSENSORS
Siemens Healthineers
A medical-technology group whose in vitro diagnostics unit includes electrochemical point-of-care devices, and which has begun preparing to carve that unit out
Siemens Healthineers comes up in any discussion of biosensors because the same company sells both bedside blood analyzers built around electrochemical sensors and large immunoassay systems for hospital laboratories. This profile covers only the Diagnostics (in vitro diagnostics) unit. According to the Annual Report for fiscal 2025 (year to September 2025), Diagnostics had adjusted revenue of €4,347 million (about 19% of Group revenue) and an adjusted EBIT margin of 7.7%. In 2026, however, revenue has fallen year on year (the company points to a structural change in the Chinese market, among other factors), and in May 2026 the company said it was preparing to carve out the unit. This profile sets out what the sensor products are, what can be confirmed from official documents, and what is not disclosed.
What this article covers
- Siemens Healthineers in 30 seconds, and where it stands in biosensors
- The logo and how the name is written
- Where the company sits in the field
- Scale
- Resources committed to biosensors
- What it has done so far
- What comes next
- What the company is aiming for in biosensors
- Map of partnerships in biosensors
- Technologies, products and services
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Siemens Healthineers in 30 seconds, and where it stands in biosensors
LEGAL NAMESiemens Healthineers AGRegistered office in Munich; main sites in Erlangen and Forchheim
LISTINGFrankfurt Stock Exchange (SHL)The parent, Siemens AG, held 68.70% on 30 September 2025
CATEGORY IN THIS FIELDIn vitro diagnostics & POCT
(analyzers and reagents)The Group's largest business is imaging; this profile covers Diagnostics only
(analyzers and reagents)The Group's largest business is imaging; this profile covers Diagnostics only
DIAGNOSTICS REVENUE (FY2025)€4,347 millionAdjusted revenue; about 19% of Group revenue (our calculation)
DIAGNOSTICS ADJUSTED EBIT MARGIN7.7%Up from 5.3%; the company credits cost reductions
Q3 FY2026 (APRIL-JUNE 2026)Revenue -5.5%
margin 4.1%Comparable basis; the company cites the Chinese market and shrinking legacy platforms
margin 4.1%Comparable basis; the company cites the Chinese market and shrinking legacy platforms
MAIN ANALYTES AND TECHNOLOGIESImmunoassay, clinical chemistry, blood gas,
HbA1c, urinalysisPoint of care uses electrochemical sensor cards and similar formats
HbA1c, urinalysisPoint of care uses electrochemical sensor cards and similar formats
COMPANY MOVEPreparing to carve out DiagnosticsForm undecided; explained by the company in May 2026
The one thing to grasp first
Siemens Healthineers is best understood not as "a biosensor company" but as "a medical-technology group with three businesses (imaging, precision therapy and in vitro diagnostics), one of which, Diagnostics, holds the sensor products" Our calculation. Within Diagnostics, the products closest to biosensors are the single-use sensor card (epoc) and the sensor-equipped measurement cartridge (RAPIDPoint) for blood gases and electrolytes, and the Atellica VTLi, which measures cardiac troponin I from a fingerstick sample Sourced. Revenue for these products alone is not disclosed. Most Diagnostics revenue probably comes from large laboratory analyzers and reagents, but that share is not disclosed either Not yet confirmed.
2. The logo and how the name is written
A note on names: the legal entity is Siemens Healthineers AG. It is a separate listed company from its parent, Siemens AG, the German industrial and electrical group. Atellica, epoc, RAPIDPoint, DCA and CLINITEK are product or brand names, not company names. The logo image was taken from the company's official website (siemens-healthineers.com).
Official site: https://www.siemens-healthineers.com/3. Where the company sits in the field
4. Scale
Until fiscal 2025 the Group reported four businesses (Imaging, Diagnostics, Varian and Advanced Therapies). From fiscal 2026, Varian, Advanced Therapies and ultrasound are combined as Precision Therapy, leaving three businesses: Imaging, Precision Therapy and Diagnostics Sourced. Because this profile is about Diagnostics, the Group as a whole is covered briefly.
| Indicator (€ million) | Fiscal 2024 | Fiscal 2025 | Change |
|---|---|---|---|
| Group revenue (IFRS) | 22,363 | 23,375 | +5.9% comparable |
| Group adjusted EBIT | 3,510 | 3,855 | +10% (margin 16.5%) |
| Diagnostics adjusted revenue | 4,417 | 4,347 | -1.6% (+0.4% comparable) |
| Diagnostics adjusted EBIT | 235 | 333 | Margin 5.3% to 7.7% |
The Group had 73,840 employees on 30 September 2025, an R&D workforce of more than 13,000, and R&D expenses of €1,958 million (8% of revenue) Sourced. Headcount and R&D spending for the Diagnostics unit alone are not given in the annual report.
| Diagnostics by period (€ million) | Adjusted revenue | Comparable growth | Adjusted EBIT margin |
|---|---|---|---|
| Fiscal 2025, full year | 4,347 | +0.4% | 7.7% |
| Fiscal 2026, Q2 (January-March) | 985 (prior year 1,122) | -6.5% | 0.9% (prior year 6.3%) |
| Fiscal 2026, Q3 (April-June) | 992 (prior year 1,059) | -5.5% | 4.1% (prior year 9.2%) |
A caution
In fiscal 2025 Diagnostics revenue in China fell by a "low double-digit percentage" (the company's wording), which the annual report attributes to centralized volume-based public procurement. In Q3 of fiscal 2026, Asia Pacific Japan grew very strongly, China fell sharply, and the Americas and EMEA each declined by a mid-single-digit percentage. Sales and growth for the sensor products alone (epoc, RAPIDPoint, VTLi) are not given in any of these documents. This article does not estimate them Not yet confirmed.
5. Resources committed to biosensors
Siemens Healthineers does not disclose R&D headcount or R&D spending for the Diagnostics unit separately, and there are no figures for the sensor products alone. The table sets out what could be confirmed.
| Resource | What primary sources confirm | Category |
|---|---|---|
| People | The Group had 73,840 employees (30 September 2025) and an R&D workforce of more than 13,000, mainly in Germany, the United States, China and India. Headcount and R&D staff for Diagnostics are not disclosed | Sourced / partly undisclosed |
| Money (R&D) | Group R&D expenses were €1,958 million (8% of revenue). The Diagnostics figure is not disclosed. The annual report names Diagnostics' focus areas as brain and metabolic health, patient-centric healthcare, AI and robotics | Sourced / partly undisclosed |
| Money (investment) | Diagnostics' additions to intangible assets and property, plant and equipment were €513 million (prior year €446 million; includes additions through business combinations). The report describes them as product development for the Atellica line (including renewal of the current blood gas and urinalysis portfolio) and production facilities in the United States, Ireland and Germany | Sourced |
| Acquisitions and investments | Epocal Inc. (maker of epoc) acquired from Abbott in 2017 (closed 31 October 2017; price undisclosed). Fast Track Diagnostics (molecular diagnostics; closed 19 December 2017). Minicare BV acquired in 2019 (closed 2 July 2019; the company says it led to the Atellica VTLi; price not confirmed here). The annual report's list of investments includes Babson Diagnostics, Inc. (United States) at a 20% interest (purpose and amount not stated) | Sourced |
| Universities, research institutions, public funding | The annual report mentions only in general terms that its "SHIFT" innovation platform works with start-ups and academic and clinical institutions. No named university or public grant specific to Diagnostics sensors could be found | Not found |
| Restructuring | Most of the fiscal 2025 impairment (€64 million across the Group) related to a Diagnostics product line being wound down as part of the transformation program; the product line is not named. The CEO said on an earnings call that the move to Atellica had reached roughly 70% of the core-lab business | Sourced |
Regulatory status (as far as could be confirmed)
The entries below were checked against the U.S. FDA 510(k) database and FDA decision documents. All are 510(k) clearances; none is a PMA approval or De Novo authorization. The database was last updated on 21 September 2026 at the time of checking Sourced.
| Product | Use (summary of the FDA document) | Category and date | Number |
|---|---|---|---|
| epoc Blood Analysis System (NXS Host) | In vitro diagnostic for trained medical professionals; quantitative testing of arterial, venous or capillary whole blood in the laboratory or at the point of care. Analytes: pH, pCO2, pO2, Na, K, ionized Ca, Cl, total CO2, glucose, lactate, blood urea nitrogen, creatinine, hematocrit | 510(k) clearance (Special), Class II. 5 June 2020. Applicant: subsidiary Epocal, Inc. | K200107 |
| RAPIDPoint 500e Blood Gas System | In vitro diagnostic. Whole-blood pCO2, pO2, pH, electrolytes, glucose, lactate, total hemoglobin and fractions, neonatal bilirubin; also pleural fluid pH. For point-of-care or laboratory settings | 510(k) clearance (Special), Class II. 27 March 2020 | K192240 |
| Atellica Solution / Atellica A-LYTE Integrated Multisensor | Multi-component in vitro diagnostic system using photometric, turbidimetric, chemiluminescent and ion-selective electrode technology. The A-LYTE multisensor quantifies Na, K and Cl in serum, plasma and urine (on Atellica CH) | 510(k) clearance, Class II. 9 March 2017 (decision date in the database) | K161954 |
| Atellica IM High-Sensitivity Troponin I (TnIH) | Chemiluminescent sandwich assay. Aids diagnosis of acute myocardial infarction; the 2024 submission added an indication to aid prognosis (all-cause mortality and major adverse cardiac events). Used on the laboratory Atellica IM Analyzer | 510(k) clearance, Class II. 25 July 2024 | K241165 |
| DCA Vantage (HbA1c analyzer) | Listed in the database as "DCA VANTAGE, MODEL 5075", product code LCP. The decision document could not be retrieved, so the use statement was not confirmed | 510(k) clearance (Special). 9 October 2007 | K071466 |
| Atellica VTLi Patient-side Immunoassay Analyzer | The company announced CE marking in April 2021. The same announcement states it is not available for sale in the U.S. Searching the FDA 510(k) database for "VTLi", "Minicare" and "Magnotech" returned no match | EU: CE mark (company announcement, 12 April 2021) / U.S.: not confirmed | - |
The status of each product under the EU In Vitro Diagnostic Regulation (IVDR), and approvals, certifications or notifications in Japan, could not be confirmed here Not yet confirmed. The annual report lists a local subsidiary, Siemens Healthcare Diagnostics K.K. (Tokyo). For how regulatory categories relate to how a device may be used, see our explainer on medical device approval categories and home use.
A materials engineer's view: what "invisible resources" tells us
The company's sensor products put electrodes, membranes, a flow path and calibration fluid together in a single-use card or cartridge. The FDA document for epoc describes a sensor array mounted in a credit-card-sized fluidic housing, with a sealed calibrator fluid reservoir Sourced. From a materials standpoint, the electrode metals, ion-selective membranes, enzyme layers, sealing materials and the calibrator pouch all bear directly on quality, and all must be produced in large volumes as disposables. Yet the annual report gives no spending on these materials or facilities, and whether the sensor materials are made in-house or bought in could not be confirmed Not yet confirmed.
6. What it has done so far
| When | Event | Meaning |
|---|---|---|
| 9 March 2017 | Atellica Solution (including the A-LYTE ion-selective electrode) received 510(k) clearance | U.S. entry for the new laboratory platform |
| 31 October 2017 | Completed the acquisition of Epocal Inc. from Abbott (announced 2 November). The company said it was "to complete its blood gas portfolio" | Gained a handheld, sensor-card blood analysis system (epoc) |
| 19 December 2017 | Completed the acquisition of molecular diagnostics company Fast Track Diagnostics (announced 11 January 2018) | Molecular diagnostics expansion; a separate line from the sensor products |
| 2 July 2019 | Completed the acquisition of Minicare BV | The company says it led to the fingerstick point-of-care immunoassay analyzer later named Atellica VTLi |
| 27 March 2020 | RAPIDPoint 500e received 510(k) clearance | Update of the cartridge-based blood gas analyzer |
| 5 June 2020 | epoc Blood Analysis System (NXS Host) received 510(k) clearance | Host device changed to a dedicated Android tablet (per the FDA document) |
| 12 April 2021 | Announced CE marking of the Atellica VTLi. The company says it gives a high-sensitivity cardiac troponin I result in eight minutes from a fingerstick | Company claim. The same announcement states it is not available for sale in the U.S. |
| 25 July 2024 | Atellica IM high-sensitivity troponin I cleared with an added prognosis indication | Laboratory assay, not point of care |
| 12 November 2025 | Parent Siemens AG announced its intention to deconsolidate Siemens Healthineers and distribute 30% of the shares to its own shareholders, preferably by direct spin-off | Separate from the Diagnostics question; concerns the listed company's ownership |
| 7 May 2026 | Q2 results: Diagnostics revenue -6.5% on a comparable basis, margin 0.9%. On the earnings call the CEO said the company was preparing to carve out Diagnostics | No form (sale, separate listing and so on) was explained |
| 31 July 2026 | Q3 results; full-year revenue outlook lowered. On the earnings call the CEO described the launch of Atellica Forte (a new laboratory series) and assays with fingerstick-capable claims | Company statement. No new point-of-care sensor product announcement could be confirmed |
7. What comes next
FY2026 REVENUE OUTLOOK (GROUP)+3.5% to +4.0% comparableLowered in Q3 (previously +4.5% to +5.0%), mainly because of Diagnostics
ADJUSTED EPS OUTLOOK€2.35 to €2.45Includes the effect of U.S. tariff refunds (company explanation)
DIAGNOSTICS Q4 EXPECTATIONMid-single-digit declineStated by the CFO on the earnings call
SIEMENS AG SPIN-OFFVote at the February 2027 AGMSubject to both AGMs and final regulatory clearance
The primary sources also describe the following plans Not yet confirmed.
- Preparing a carve-out of Diagnostics. The CEO said this is to keep a wide range of paths open. Whether it would be sold, listed separately or retained has not been explained. The CFO said any separation costs would be treated as an adjusting item if they occurred
- The CEO said that, at the November 2025 capital markets day, Diagnostics was announced to have "its own strategy and its own setup" (that presentation was not reviewed here)
- Rollout of Atellica Forte. The company says it has 24 assays with CE-marked capillary claims (the CE-mark category and countries were not checked)
- A neurofilament light chain assay said to be under FDA review. This is a laboratory immunoassay, not a biosensor product
What could not be confirmed
Sales, unit volumes and R&D spending for epoc, RAPIDPoint and VTLi alone / the status of any FDA submission for VTLi / the materials and suppliers behind the sensors / Diagnostics headcount and R&D spending / named university or public-sector research collaborations / the IVDR and Japanese status of each product / the form and timing of the carve-out. None appears in the official documents retrieved.
8. What the company is aiming for in biosensors
This section separates what the company says it is aiming for from what this article reads into the record. Inference marks interpretation drawn by this article from primary sources.
| What can be read | Primary source behind it | Category |
|---|---|---|
| It intends to move testing closer to the patient | The official pages' language about "the right test in the right place at the right time", its point-of-care lines for blood gas, cardiac, diabetes and urine, and the annual report's focus on patient-centric healthcare | Sourced (company explanation) |
| It is renewing its blood gas portfolio | The annual report lists "renewal of the current blood gas and urinalysis portfolio" among Diagnostics' additions to intangible assets. The latest FDA clearances found for epoc and RAPIDPoint date from 2020 | Sourced / Inference (which product comes next is unknown) |
| The point-of-care immunoassay (VTLi) may not yet be on the U.S. market | The 2021 announcement says it is not available in the U.S.; no match in the FDA database; the official page still lists the product today | Inference (unconfirmed; this does not mean no submission exists) |
| It is moving Diagnostics away from the Group's core | The CEO said he is preparing a carve-out of Diagnostics and called the other two businesses the "synergetic core" | Sourced (company explanation) / Inference (what comes after) |
| It is making new laboratory platforms its main axis | The launch of Atellica Forte, and the CEO's statement that Atellica accounts for roughly 70% of core lab | Sourced (company explanation) |
One inference, explained in more detail
The reading that "Diagnostics is moving away from the core" rests on the company's own choice of words. On the May 2026 earnings call the CEO called Imaging and Precision Therapy the "synergetic core", and said that for Diagnostics the company was preparing a carve-out to keep a range of paths open Sourced. In the same period Diagnostics revenue fell on the structural change in China and its margin dropped to 0.9%. However, the company has not said whether the carve-out would mean a sale or a standalone company. And remarks on an earnings call reflect management's intentions; they are not a decision of the board or of shareholders Not yet confirmed.
9. Map of partnerships in biosensors
Neither the annual report nor the official announcements name co-development partners or suppliers of parts for the sensor products. The relationships that can be confirmed from primary sources are therefore acquisitions, investments and the link to the parent only Sourced. The 2017 announcement says Abbott was the seller of Epocal. Abbott is also a competitor in diagnostics, but it appears here only as the counterparty to a sale, not as a technology partner.
10. Technologies, products and services
On the official site, the point-of-care (POC) products fall into four groups: urinalysis, blood gas, diabetes and informatics (POC Informatics). The emergency-department page also lists a cardiac test (Atellica VTLi) Sourced. All figures below are manufacturer's stated values (official pages). Test conditions and editions differ, so no ranking is made between products, or against other companies' products.
| Category | What the official sources say | Comment |
|---|---|---|
| Blood gas: epoc Blood Analysis System | Handheld and wireless. One room-temperature test card covers blood gases, a basic metabolic panel, hematocrit and lactate. Sample of at least 92 µL; result in under one minute. Storage 15-30°C; shelf life up to five months. Calibration is automatic before every test (FDA document: calibrator fluid inside the card) | Manufacturer's stated values. An electrochemical multi-sensor array (per the FDA document). See our explainer on electrochemical sensors |
| Blood gas: RAPIDPoint 500e | Benchtop, cartridge-based. The measurement cartridge contains the planar sensors, sample probe and CO-oximetry chamber and is replaced as a unit. Sample 100 µL; result in about 60 seconds. Measurement cartridge use life is 28 days onboard or a maximum number of tests; initialization about 24 minutes | Manufacturer's stated values. Principle: potentiometry, amperometry and conductimetry (FDA document) plus optical CO-oximetry |
| Cardiac: Atellica VTLi | A handheld patient-side immunoassay analyzer that measures high-sensitivity cardiac troponin I from a fingerstick. Result in eight minutes (company announcement). The emergency-department page says it uses "Magnotech Technology". CE marked in 2021; the announcement stated it was not available in the U.S. | Company claim. The measurement principle behind Magnotech was not confirmed from a primary source here |
| Diabetes: DCA Vantage / Atellica DCA | Analyzers for HbA1c and urine albumin-to-creatinine ratio (ACR). Atellica DCA is marked "not available for sale in the U.S.". HbA1c results "in minutes" and ACR in 7 minutes (Atellica DCA page) | Not a continuous or self-monitoring glucose device. Instruments for healthcare professionals |
| Urinalysis and other POC | The CLINITEK series (urinalysis), CLINITEST hCG (pregnancy test), RAPIDLab 1200 and 348EX (blood gas) and POCcelerator (POC device data management; the official page cites more than 230 device interfaces from 70+ manufacturers) | Informatics supports running POC devices from the laboratory's viewpoint |
| Laboratory | Atellica Solution (clinical chemistry, immunoassay, ion-selective electrode), Atellica CI Analyzer, and Atellica Forte launched in 2026 (company statement). The annual report lists immunochemistry, hematology, hemostasis, urinalysis, diabetes care and blood gas among its testing disciplines | Most Diagnostics revenue probably comes from the laboratory side, but the share is not disclosed |
A materials engineer's view: where materials matter in a single-use sensor card
According to the FDA document, the epoc test card combines a sensor array, a sealed calibrator fluid and a sample flow path in one small disposable housing Sourced. In that format, the stated shelf life of up to five months at room temperature (15-30°C) sets the demands on the materials. The calibrator must not leak or evaporate from its pouch, the ion-selective membranes and enzyme layers must not degrade in storage, and the bond between electrodes and membranes must hold Not yet confirmed. The RAPIDPoint takes a different design: the sensors, sample probe and CO-oximetry chamber sit in one cartridge whose use life is set per cartridge (official page). In both, putting the sensor on the consumable side separates sensor aging from instrument maintenance.
However, the specific electrode metals, membrane materials, enzymes and sealants are not given in the documents retrieved. The above describes general requirements that can be read from the format; how individual products meet them was not checked. For the underlying ideas, see our explainers on enzyme and electrode interface materials, electrochemical sensors and POCT.
11. The risks this company carries
| Risk | Detail | Category |
|---|---|---|
| Structural change in China | Because of volume-based procurement and price pressure, Diagnostics revenue in China fell by a "low double-digit percentage" in fiscal 2025, and China fell sharply again in Q2 and Q3 of fiscal 2026. The company calls it a "structural market rebasing" | Sourced |
| Weaker earnings | The Diagnostics margin went from 7.7% in fiscal 2025 to 0.9% in Q2 and 4.1% in Q3 of fiscal 2026. The company cites lower revenue, product mix and currency | Sourced |
| Shrinking legacy platforms | The CFO said the dilution from declining legacy platforms continues. The annual report records an impairment tied to winding down one Diagnostics product line | Sourced |
| Carve-out and parent spin-off | The form of the Diagnostics carve-out is undecided. Siemens AG's distribution of shares also depends on both AGMs and final regulatory clearance. The effect on strategy, staff and customer contracts cannot be confirmed at present | Not yet confirmed |
| Tariffs | The annual report and quarterly documents say U.S. tariffs affected the margins of all segments. In February 2026 the U.S. Supreme Court struck down tariffs imposed under IEEPA, and refunds were included in Q3 earnings | Sourced |
| Renewal timing for sensor POC products | The latest FDA clearances found for epoc and RAPIDPoint 500e date from 2020. The company says it is investing in renewing its blood gas portfolio, but no new product name could be confirmed | Inference |
| U.S. position of VTLi | The 2021 announcement said it was not sold in the U.S., and no match was found in the FDA database. The current status was not confirmed here | Sourced / not confirmed |
| Hard to verify the sensor business | Sales, profit and R&D for the sensor products are all undisclosed, so the scale of the business is hard to check from outside | Not yet confirmed |
12. Glossary
- POCT (point-of-care testing)
- Testing performed near the patient. Results come quickly, but quality control and record-keeping have to be organized separately.
- IVD (in vitro diagnostic)
- A test performed on a sample taken from the body, such as blood or urine.
- 510(k) clearance
- The U.S. FDA route for devices found substantially equivalent to a device already on the market. Distinct from PMA approval and De Novo authorization.
- Blood gas
- A test of the partial pressures of oxygen and carbon dioxide and the pH of blood. Many analyzers also measure electrolytes and lactate at the same time.
- Ion-selective electrode (ISE)
- An electrode with a membrane that responds to a specific ion (Na, K, Cl and so on). Concentration is derived from the electrical potential.
- CO-oximetry
- A method that uses light absorption to measure the forms of hemoglobin, such as oxygen-bound and carbon-monoxide-bound.
- Chemiluminescent immunoassay
- A method that captures a target substance with antibodies and measures the amount by the intensity of emitted light. Widely used in laboratory immunoassay analyzers.
- High-sensitivity troponin I (hs-cTnI)
- A test that measures a heart-muscle protein in the blood from very low concentrations. How to read the result is a matter for healthcare professionals.
- Adjusted revenue and comparable growth
- Revenue stripped of certain accounting effects, and growth stripped of currency and acquisition or disposal effects. The company uses them to compare performance.
- Volume-based procurement
- A scheme in China in which public bodies buy in bulk to push prices down. The annual report says it intensified price pressure in China's diagnostics market.
- Carve-out
- Separating part of a company so that it can operate independently. What follows (sale, separate listing and so on) can take many forms.
13. References
- Siemens Healthineers Annual Report 2025 (published November 2025). Business description; segment revenue, profit and investment; R&D spending and staff; employee numbers; list of acquired companies and investments; Siemens AG's shareholding and spin-off intention; impairment; Diagnostics market discussion. https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf
- Siemens Healthineers Half-Year Financial Report 2026 (to 31 March 2026). New segment structure; U.S. Supreme Court decision on IEEPA tariffs; clarification of the Siemens AG spin-off timeline (17 April 2026). https://corporate.webassets.siemens-healthineers.com/63754e6195b8d00c/6a6087ac45c9/siemens-healthineers-Q2_FY2026_Half-Year-Financial-Report.pdf
- Siemens Healthineers Q2 Fiscal Year 2026 Earnings Release (7 May 2026). Diagnostics revenue and margin for Q2 and the regional commentary. https://corporate.webassets.siemens-healthineers.com/f973516aefed9689/c59e0c690a69/siemens-healthineers-Q2_FY2026_Earnings-Release-and-Financial-Results..pdf
- Siemens Healthineers Q3 Fiscal Year 2026 Earnings Release (31 July 2026). Diagnostics revenue and margin for Q3; updated full-year outlook. https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3_FY2026_Earnings-Release-and-Financial-Results.pdf
- Siemens Healthineers Q2 FY2026 earnings call transcript (7 May 2026; posted on the company's investor-relations site, prepared by LSEG). CEO remarks on preparing the Diagnostics carve-out and on progress of the move to Atellica. https://corporate.webassets.siemens-healthineers.com/73c0b165655db327/a9aaa85621f2/siemens-healthineers-Q2_FY2026_Analyst-call-transcript.pdf
- Siemens Healthineers Q3 FY2026 earnings call transcript (31 July 2026; posted on the investor-relations site, prepared by LSEG). Remarks on the Atellica Forte launch, the Diagnostics Q4 expectation and the treatment of separation costs. https://corporate.webassets.siemens-healthineers.com/91e2e22c76fbf662/beca9eeb382f/siemens-healthineers-Q3_FY2026_Analyst-call-transcript.pdf
- Siemens Healthineers Press release "Expediting the Diagnosis of Heart Attack with Atellica VTLi Patient-Side Analyzer for Industry First Fingerstick High-Sensitivity Troponin I at Point-of-Care" (12 April 2021). CE mark, eight minutes, completion date of the Minicare BV acquisition (2 July 2019) and the note that it is not available in the U.S. https://www.siemens-healthineers.com/press/releases/atellica-vtli
- Siemens Healthineers Press release "Siemens Healthineers Announces Closing of Epocal Acquisition" (2 November 2017). https://www.siemens-healthineers.com/press/releases/pr-2017110065hcen.html
- Siemens Healthineers Press release "Siemens Healthineers announces closing of Fast Track Diagnostics acquisition" (11 January 2018). https://www.siemens-healthineers.com/press/releases/pr-2018010127hc.html
- Siemens Healthineers Point of Care Testing in Emergency Departments (product guide for emergency departments). Lists Atellica VTLi, epoc, RAPIDPoint 500e and CLINITEST. https://www.siemens-healthineers.com/point-of-care-testing/poct-by-clinical-setting/hospitals-and-emergency-departments
- Siemens Healthineers epoc Blood Analysis System (product page). Sample volume, time to result, storage conditions, shelf life and measurement ranges; manufacturer's stated values. https://www.siemens-healthineers.com/blood-gas/blood-gas-systems/epoc-blood-analysis-system
- Siemens Healthineers RAPIDPoint 500e Blood Gas System (product page). Cartridge design, sample volume, time to result and use life; manufacturer's stated values. https://www.siemens-healthineers.com/blood-gas/blood-gas-systems/rapidpoint-500e-systems
- Siemens Healthineers Diabetes (point-of-care diabetes testing product page). DCA Vantage and Atellica DCA. https://www.siemens-healthineers.com/diabetes
- Siemens Healthineers Point-of-Care Testing (point-of-care product overview). Four groups: urinalysis, blood gas, diabetes and informatics. https://www.siemens-healthineers.com/point-of-care-testing
- U.S. Food and Drug Administration 510(k) K200107 "epoc Blood Analysis System": clearance letter and 510(k) summary (5 June 2020). Intended use, analytes and sensor-array design. https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200107.pdf
- U.S. Food and Drug Administration 510(k) K192240 "RAPIDPoint 500e Blood Gas System": clearance letter and 510(k) summary (27 March 2020). Intended use and measurement principle. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192240.pdf
- U.S. Food and Drug Administration 510(k) K161954 "Atellica Solution, Atellica A-LYTE Integrated Multisensor": clearance letter and summary. https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161954.pdf
- U.S. Food and Drug Administration 510(k) K241165 "Atellica IM High-Sensitivity Troponin I (TnIH)": clearance letter and summary (25 July 2024). https://www.accessdata.fda.gov/cdrh_docs/pdf24/K241165.pdf
- U.S. Food and Drug Administration (openFDA) 510(k) database API (the record for K071466 "DCA Vantage"; the database was last updated on 21 September 2026). The searches reported here as "no match found" were also run through this API. https://api.fda.gov/device/510k.json?search=k_number:K071466
- Siemens Healthineers Official website (source of the logo image). https://www.siemens-healthineers.com/
- Siemens Healthineers Press release on the second-quarter results (7 May 2026). Company profile (listing and ticker, fiscal 2025 headcount and revenue) and the CEO's comment. https://www.siemens-healthineers.com/press/releases/2026q2
14. Claim-to-source audit
| Claim in the text | Category | Source |
|---|---|---|
| Legal name, registered office (Munich), main sites (Erlangen, Forchheim), 73,840 employees, more than 13,000 R&D staff, R&D expenses of €1,958 million | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Listing (Frankfurt, ticker SHL) | Sourced | Reference 21 https://www.siemens-healthineers.com/press/releases/2026q2 |
| Siemens AG holds 68.70% (30 September 2025); intention announced on 12 November 2025 to distribute 30% (preferably by direct spin-off) | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| On 17 April 2026 Siemens AG clarified the timeline (resolution sought at the AGM in February 2027); final regulatory clearance and approval by both AGMs are conditions | Sourced | Reference 2 https://corporate.webassets.siemens-healthineers.com/63754e6195b8d00c/6a6087ac45c9/siemens-healthineers-Q2_FY2026_Half-Year-Financial-Report.pdf |
| Change of segment structure (three businesses from fiscal 2026: Imaging, Precision Therapy, Diagnostics) | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf Reference 2 https://corporate.webassets.siemens-healthineers.com/63754e6195b8d00c/6a6087ac45c9/siemens-healthineers-Q2_FY2026_Half-Year-Financial-Report.pdf |
| Definition of Diagnostics (in vitro diagnostic products and services for general laboratory, specialty laboratory and point of care) and testing disciplines | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Diagnostics fiscal 2025 adjusted revenue €4,347 million (prior year €4,417 million), +0.4% comparable, adjusted EBIT €333 million, margin 7.7% (prior year 5.3%) | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Group revenue €23,375 million, adjusted EBIT €3,855 million (prior year €3,510 million), margin 16.5%, comparable growth +5.9% | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Diagnostics at about 19% of Group revenue | Our calculation | Our own division (€4,347 million / €23,375 million). The numerator is segment adjusted revenue and the denominator is IFRS Group revenue, so the definitions differ slightly. The company does not disclose this share |
| "Low double-digit" decline in China in fiscal 2025, attributed to volume-based procurement | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Diagnostics Q2 revenue €985 million (-6.5% comparable), margin 0.9% (prior year 6.3%) | Sourced | Reference 3 https://corporate.webassets.siemens-healthineers.com/f973516aefed9689/c59e0c690a69/siemens-healthineers-Q2_FY2026_Earnings-Release-and-Financial-Results..pdf |
| Diagnostics Q3 revenue €992 million (-5.5% comparable), margin 4.1% (prior year 9.2%) and the regional commentary | Sourced | Reference 4 https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3_FY2026_Earnings-Release-and-Financial-Results.pdf |
| Diagnostics additions of €513 million (prior year €446 million) and the description of them (Atellica line development, renewal of blood gas and urinalysis portfolio, production facilities in the U.S., Ireland and Germany) | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Impairment tied to winding down one Diagnostics product line (most of the Group's €64 million impairment) | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Completion of the Epocal Inc. acquisition (31 October 2017, from Abbott, price undisclosed) | Sourced | Reference 8 https://www.siemens-healthineers.com/press/releases/pr-2017110065hcen.html |
| Completion of the Fast Track Diagnostics acquisition (19 December 2017, terms undisclosed) | Sourced | Reference 9 https://www.siemens-healthineers.com/press/releases/pr-2018010127hc.html |
| Completion of the Minicare BV acquisition (2 July 2019) and the company's statement that it led to the Atellica VTLi | Sourced | Reference 7 https://www.siemens-healthineers.com/press/releases/atellica-vtli |
| Babson Diagnostics, Inc. (U.S.) listed as an investment at a 20% interest | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| The SHIFT collaboration with start-ups, universities and clinical institutions (general), Innovation Centers (Erlangen, Shanghai, Bengaluru) | Sourced | Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Named universities or public grants specific to Diagnostics sensors | Not yet confirmed | Not in Reference 1. Not found. We do not claim that none exists Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Diagnostics headcount and R&D spending; sales or unit volumes for the sensor products alone | Not yet confirmed | Not in References 1 and 4. Not estimated in this article Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf Reference 4 https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3_FY2026_Earnings-Release-and-Financial-Results.pdf |
| FDA 510(k) clearance of epoc (K200107, 5 June 2020), its use, analytes, sensor array and calibrator design | Sourced | Reference 15 https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200107.pdf |
| FDA 510(k) clearance of RAPIDPoint 500e (K192240, 27 March 2020), its use and measurement principles (potentiometry, amperometry, conductimetry and optical) | Sourced | Reference 16 https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192240.pdf |
| FDA 510(k) clearance of Atellica Solution and the A-LYTE Integrated Multisensor (K161954) | Sourced | Reference 17 https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161954.pdf |
| FDA 510(k) clearance of Atellica IM high-sensitivity troponin I (K241165, 25 July 2024) and the added prognosis indication | Sourced | Reference 18 https://www.accessdata.fda.gov/cdrh_docs/pdf24/K241165.pdf |
| Database record for DCA Vantage (K071466, 9 October 2007, product code LCP); the use statement could not be retrieved | Sourced | Reference 19 https://api.fda.gov/device/510k.json?search=k_number:K071466 |
| CE marking of Atellica VTLi (April 2021), eight minutes, and the note that it is not available in the U.S. | Sourced | Reference 7 https://www.siemens-healthineers.com/press/releases/atellica-vtli |
| Atellica VTLi listed in the emergency-department guide, and the "Magnotech Technology" wording | Sourced | Reference 10 https://www.siemens-healthineers.com/point-of-care-testing/poct-by-clinical-setting/hospitals-and-emergency-departments |
| No match in the FDA 510(k) database (updated 21 September 2026) for "VTLi", "Minicare" or "Magnotech" | Not yet confirmed | Our own search. Not confirmed; we do not claim that no submission or clearance exists Reference 19 https://api.fda.gov/device/510k.json?search=k_number:K071466 |
| Status under IVDR and in Japan | Not yet confirmed | Not in the documents retrieved. Not confirmed Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| epoc specifications (sample of at least 92 µL, under one minute, storage 15-30°C, shelf life up to five months, one room-temperature card) | Sourced | Manufacturer's stated values (official page). Reference 11 https://www.siemens-healthineers.com/blood-gas/blood-gas-systems/epoc-blood-analysis-system |
| RAPIDPoint 500e specifications (sample 100 µL, about 60 seconds, 28-day use life, cartridge contents) | Sourced | Manufacturer's stated values (official page). Reference 12 https://www.siemens-healthineers.com/blood-gas/blood-gas-systems/rapidpoint-500e-systems |
| DCA Vantage and Atellica DCA (not available in the U.S.), ACR in 7 minutes | Sourced | Reference 13 https://www.siemens-healthineers.com/diabetes |
| Point-of-care groups (urinalysis, blood gas, diabetes, informatics) and POCcelerator (more than 230 device interfaces) | Sourced | Reference 10 https://www.siemens-healthineers.com/point-of-care-testing/poct-by-clinical-setting/hospitals-and-emergency-departments Reference 14 https://www.siemens-healthineers.com/point-of-care-testing |
| FY2026 outlook (revenue +3.5% to +4.0%, adjusted EPS €2.35 to €2.45) | Not yet confirmed | Reference 4 https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3_FY2026_Earnings-Release-and-Financial-Results.pdf |
| Preparing the Diagnostics carve-out, "keep a range of paths open", and the November 2025 announcement of its own strategy and setup | Not yet confirmed | Reference 5 https://corporate.webassets.siemens-healthineers.com/73c0b165655db327/a9aaa85621f2/siemens-healthineers-Q2_FY2026_Analyst-call-transcript.pdf |
| Diagnostics Q4 mid-single-digit decline expectation, treatment of separation costs, Atellica Forte launch, 24 fingerstick-capable assays | Not yet confirmed | Reference 6 https://corporate.webassets.siemens-healthineers.com/91e2e22c76fbf662/beca9eeb382f/siemens-healthineers-Q3_FY2026_Analyst-call-transcript.pdf |
| The CEO's statement that the move to Atellica reached about 70% of core lab | Sourced | Reference 5 https://corporate.webassets.siemens-healthineers.com/73c0b165655db327/a9aaa85621f2/siemens-healthineers-Q2_FY2026_Analyst-call-transcript.pdf |
| Reading that Diagnostics intends to move testing closer to the patient | Inference | This article's interpretation. Reference 10 https://www.siemens-healthineers.com/point-of-care-testing/poct-by-clinical-setting/hospitals-and-emergency-departments Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf |
| Reading that a next-generation blood gas product may exist, from the portfolio renewal and the 2020 clearance dates | Inference | This article's interpretation. Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf Reference 15 https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200107.pdf Reference 16 https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192240.pdf |
| Reading that VTLi may not yet be on the U.S. market | Inference | This article's interpretation. Unconfirmed; not the same as no submission. Reference 7 https://www.siemens-healthineers.com/press/releases/atellica-vtli Reference 19 https://api.fda.gov/device/510k.json?search=k_number:K071466 |
| Reading that Diagnostics is moving away from the Group's core | Inference | This article's interpretation. Reference 5 https://corporate.webassets.siemens-healthineers.com/73c0b165655db327/a9aaa85621f2/siemens-healthineers-Q2_FY2026_Analyst-call-transcript.pdf |
| The risk framing: renewal timing of sensor products, shrinking legacy platforms, tariffs, price pressure in China | Inference | This article's interpretation. Reference 1 https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf Reference 2 https://corporate.webassets.siemens-healthineers.com/63754e6195b8d00c/6a6087ac45c9/siemens-healthineers-Q2_FY2026_Half-Year-Financial-Report.pdf Reference 4 https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3_FY2026_Earnings-Release-and-Financial-Results.pdf Reference 6 https://corporate.webassets.siemens-healthineers.com/91e2e22c76fbf662/beca9eeb382f/siemens-healthineers-Q3_FY2026_Analyst-call-transcript.pdf |
| The four types of company (diabetes and continuous monitoring / in vitro diagnostics and POCT / wearables and consumer devices / materials and components) and the example company names | Our calculation | Our own classification. Company names are examples from the companies covered in this series |
| A materials engineer's view: shelf life of the test card and demands on materials | Inference | This article's interpretation. Specific materials are not stated in the documents retrieved and were not checked. Reference 11 https://www.siemens-healthineers.com/blood-gas/blood-gas-systems/epoc-blood-analysis-system Reference 15 https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200107.pdf |
Last updated 4 October 2026 / Troy Technical
Every figure in this article comes from Siemens Healthineers' annual report, quarterly documents and official announcements, and from FDA public documents. No research-firm estimates or press-based figures have been used (the company's own estimate of its addressable market in the annual report is not used either). Passages marked "Inference" are this article's interpretation of primary sources, not statements made by the company. Earnings-call transcripts record statements by management; they are not decisions of the board or of shareholders.